Prognostic value of 1q21 amplification in multiple myeloma
Tatiana Abramova(Ministry of Health of the Russian Federation), Savchenko Vg(National Research Center for Hematology Russian Academy of Medical Sciences), С. М. Куликов(Ministry of Health of the Russian Federation), Т. Н. Обухова(Ministry of Health of the Russian Federation), Л. П. Менделеева(National Research Center for Hematology Russian Academy of Medical Sciences), M A Rusinov(Ministry of Health of the Russian Federation), O. M. Votyakova(Russian Cancer Research Center NN Blokhin), Е О Грибанова, L. A. Grebenyuk(Ministry of Health of the Russian Federation), Olga S. Pokrovskaya, Maria V. Nareyko(Ministry of Health of the Russian Federation), M. V. Solovyev(Ministry of Health of the Russian Federation), В В Рыжко
Cited by 4
Related Papers
Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation
|Bone Marrow Transplantation|2014|195
Atlas of RNA sequencing profiles for normal human tissues
|Scientific Data|2019|142
Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective
|The Oncologist|2010|92
Thromboelastography, thrombin generation test and thrombodynamics reveal hypercoagulability in patients with multiple myeloma
|Leukemia & lymphoma/Leukemia and lymphoma|2015|59